menu search

Travere therapeutics to present abstracts at the american society of nephrology (asn) kidney week 2023

Two late-breaking high-impact oral presentations of the Phase 3 PROTECT study of FILSPARI® (sparsentan...

October 13, 2023, 8:30 pm

Mind medicine: q4 of 2023 data for gad makes this worth a look

Results from the phase 2b study, using MM-120 for the treatment of patients with generalized anxiety disorder, expected Q4 of 2023. The Generalized An...

October 13, 2023, 6:37 pm

Kronos bio presents positive preliminary data from phase 1 dose escalation portion of phase 1/2 kb-0742 study at aacr-nci-eortc

Demonstrated on-mechanism, single agent anti-tumor activity in heavily pre-treated patients with transcriptionally addicted solid tumors Showed manage...

October 13, 2023, 4:30 pm

Travere therapeutics to present abstracts at the american society of nephrology (asn) kidney week 2023

Two late-breaking high-impact oral presentations of the Phase 3 PROTECT study of FILSPARI ® (sparsenta...

October 13, 2023, 4:30 pm

Harmony stock tanks on study miss for narcolepsy drug: problems may be escalating

Harmony Biosciences' only product, WAKIX - pitolisant - has generated over $1 billion in net revenue since its launch. The company's Q2 2023 earnings ...

October 13, 2023, 4:01 pm

Eur/usd weekly forecast: bears return with a vengeance

The FXStreet Forecast Poll suggests bulls will likely battle to regain control. EUR/USD buyers are a majority in all the time frame under study, while...

October 13, 2023, 3:59 pm

Vera therapeutics to present three posters at the american society of nephrology kidney week 2023 annual meeting

Informational poster for ORIGIN 3 Pivotal Phase 3 study evaluating atacicept in IgA Nephropathy (IgAN) ...

October 13, 2023, 2:22 pm

Annovis (anvs) ad study to continue as planned, shares rise

Annovis (ANVS) gains on the release of interim independent analysis, indicating that the ongoing phase II/III ...

October 13, 2023, 2:16 pm

Eli lilly's (lly) mirikizumab meets crohn's disease study goals

Based on this data, Eli Lilly (LLY) will initiate regulatory submissions worldwide next year seeking regulatory approval for mirikizumab in Crohn's di...

October 13, 2023, 1:31 pm

Harmony biosciences stock drops on disappointing study results

Harmony Biosciences Holdings Inc shares sank 38% to $18.66 in late-morning trading on Friday after the pharmaceutical company reported topline results...

October 13, 2023, 11:29 am

Vera therapeutics to present three posters at the american society of nephrology kidney week 2023 annual meeting

Informational poster for ORIGIN 3 Pivotal Phase 3 study evaluating atacicept in IgA Nephropathy (IgAN) ...

October 13, 2023, 10:22 am

Alpine immune sciences to present initial clinical data on povetacicept in autoimmune glomerulonephritis in a late breaker poster session at american society of nephrology kidney week 2023

SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative...

October 13, 2023, 9:05 am

Abbvie's (abbv) rinvoq meets key goal in phase ii vitiligo study

AbbVie (ABBV) meets the primary goal in the phase II study evaluating Rinvoq in the treatment of adult ...

October 13, 2023, 8:16 am

Block sack market gears up for an impressive valuation of us$ 1.8 billion by 2033, piloting in a new era of storage solutions | future market insights, inc.

According to Future Market Insight’s research study, the Block Sack Market thrives on eco-friendly construction, adaptability, and recycled material...

October 13, 2023, 1:30 am

Biocardia (bcda) up on plans for second heart failure study

BioCardia (BCDA) completes enrollment in a pivotal phase III study on its CardiAMP cell therapy for the...

October 12, 2023, 12:47 pm

Incyte (incy) posts upbeat data from phase ii vitiligo study

Incyte (INCY) announces new positive 52-week data from its mid-stage study of povorcitinib for the trea...

October 12, 2023, 12:47 pm

Tempest (tpst) up as first-line liver cancer study meets goals

Tempest (TPST) skyrockets 2879% on positive new and updated findings from its early-mid-stage study eva...

October 12, 2023, 12:01 pm

Eli lilly stock hits new high on positive crohn's disease study results

Eli Lilly and Co (NYSE:LLY) announced on Thursday that its drug development candidate, mirikizumab, met the main goals of a late-stage ...

October 12, 2023, 8:35 am

Optical coherence tomography (oct) for ophthalmology market to reach us$ 6.5 billion by 2032 | fact.mr

Increasing Healthcare Spending and Demand for Advanced Optical Imaging Systems are driving up Sales in the United Kingdom Rockville , Oct. 12, 2023 (G...

October 12, 2023, 7:00 am

Air spring components market to hit us$ 2.06 billion by 2033: fact.mr analysis

Integration of Electronic Control Systems Increasing Efficiency of Air Spring Components Rockville , Oct. 11, 2023 (GLOBE NEWSWIRE) — According to a...

October 11, 2023, 10:00 pm


Search within

Pages Search Results: